Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lori D Bash

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Advances in Therapy|April 19, 2021
A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the USYiling Jiang, Lori D Bash, Leif Saager
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 26, 2009
Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) StudyLori D Bash, Brad C Astor, Josef Coresh
Anesthesia and Analgesia|November 16, 2021
Neuromuscular Blockade and Reversal Practice Variability in the Outpatient Setting: Insights From US Utilization PatternsLori D Bash, Wynona Black, Vladimir Turzhitsky, et al.
Advances in Therapy|July 28, 2021
Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical SettingsLori D Bash, Vladimir Turzhitsky, Wynona Black, et al.
Journal of Managed Care & Specialty Pharmacy|August 31, 2017
Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary SyndromeAmi Vyas, Lori D Bash, Mehul D Patel, et al.
Archives of Internal Medicine|December 10, 2008
Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) StudyLori D Bash, Elizabeth Selvin, Michael Steffes, et al.
European Journal of Internal Medicine|March 25, 2017
Differences in short and long-term survival between males and females with new-onset heart failure: A retrospective cohort studyGabriel Chodick, Dahlia Weitzman, Robert O Blaustein, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 2, 2010
Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) StudyKunihiro Matsushita, Elizabeth Selvin, Lori D Bash, et al.
JMIR Perioperative Medicine|July 22, 2024
Factors Influencing Neuromuscular Blockade Reversal Choice in the United States Before and During the COVID-19 Pandemic: Retrospective Longitudinal AnalysisVladimir Turzhitsky, Lori D Bash, Richard D Urman, et al.
Journal of Clinical Anesthesia|April 19, 2020
Incidence of residual neuromuscular blockade and use of neuromuscular blocking agents with or without antagonists: A systematic review and meta-analysis of randomized controlled trialsAmit D Raval, Jennifer Uyei, Andreas Karabis, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Advances in Therapy|April 19, 2021
A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the USYiling Jiang, Lori D Bash, Leif Saager
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 26, 2009
Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) StudyLori D Bash, Brad C Astor, Josef Coresh
Anesthesia and Analgesia|November 16, 2021
Neuromuscular Blockade and Reversal Practice Variability in the Outpatient Setting: Insights From US Utilization PatternsLori D Bash, Wynona Black, Vladimir Turzhitsky, et al.
Advances in Therapy|July 28, 2021
Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical SettingsLori D Bash, Vladimir Turzhitsky, Wynona Black, et al.
Journal of Managed Care & Specialty Pharmacy|August 31, 2017
Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary SyndromeAmi Vyas, Lori D Bash, Mehul D Patel, et al.
Archives of Internal Medicine|December 10, 2008
Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) StudyLori D Bash, Elizabeth Selvin, Michael Steffes, et al.
European Journal of Internal Medicine|March 25, 2017
Differences in short and long-term survival between males and females with new-onset heart failure: A retrospective cohort studyGabriel Chodick, Dahlia Weitzman, Robert O Blaustein, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 2, 2010
Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) StudyKunihiro Matsushita, Elizabeth Selvin, Lori D Bash, et al.
JMIR Perioperative Medicine|July 22, 2024
Factors Influencing Neuromuscular Blockade Reversal Choice in the United States Before and During the COVID-19 Pandemic: Retrospective Longitudinal AnalysisVladimir Turzhitsky, Lori D Bash, Richard D Urman, et al.
Journal of Clinical Anesthesia|April 19, 2020
Incidence of residual neuromuscular blockade and use of neuromuscular blocking agents with or without antagonists: A systematic review and meta-analysis of randomized controlled trialsAmit D Raval, Jennifer Uyei, Andreas Karabis, et al.
Pageof 7